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idespread variations in the diagnosis and manage-
ment of clinical conditions have been noted for
many years. This is particularly true when there is uncer-
tainty regarding the benefits and risks associated with
different decisions. One area in which such substantial
uncertainty remains is the screening and treatment of
prostate cancer. Although prostate-specific antigen (PSA)
testing has been available since 1987, in the absence of
randomized controlled trials demonstrating that PSA




Lack of consensus also exists regarding the optimal treat-
ment for patients with clinically localized prostate cancer.
Aggressive treatment options include radiation therapy and
radical prostatectomy. While survival outcomes are similar
for these alternative treatments, physician recommenda-
tions vary by specialty, with radiation oncologists advocat-





Two articles in this issue of 
 
Journal of General Internal
Medicine
 
 examine different aspects of prostate cancer screen-
ing and treatment. Frosch et al. conducted a randomized
controlled trial to evaluate the effectiveness of two methods
for delivering educational material—videotape and the




Patients randomized to the video group had greater increases
in PSA knowledge and were more likely to decline PSA test-
ing than those in the internet group. However, video patients,
who were required to dedicate a specific time to viewing the
video, were more likely to have reviewed all the material
compared to the internet patients. When comparing PSA
knowledge and PSA testing decisions of patients in the
video and internet groups who reviewed the same material
there were no significant differences between groups.
These results apply most directly to the kinds of
patients studied, i.e., well-educated, white men with
access to the internet who elect to undergo a free annual
routine physical examination (assuming most of the men
were enrolled in Kaiser Permanente’s health plan). In con-
trast to a previous study, which compared videotape and
discussion in educating patients about PSA in the same
setting, where 22% of participants were minorities and 20%





study had 10% minority participation and only 7% had a
high school or lower level of education. Thus, by requiring
internet access in this study, the numbers of minorities
and less educated individuals who could use this decision
aid were reduced. Similarly, the fact that PSA testing was
free eliminates financial barriers that can be a significant




In the second paper, Hoffman et al. examine whether





 For the one third of men with more
aggressive prostate cancers, African Americans were less
likely to receive radical prostatectomy than whites and
more likely to be treated by androgen deprivation or watch-
ful waiting. No significant racial differences were found in
treating men with less aggressive cancers and the differ-
ences noted among men with aggressive cancers are not
explained by the intensiveness of evaluating the disease.
Are African Americans with aggressive cancers under-
going too few radical prostatectomies or are whites under-
going too many? The present study has no definitive criteria
regarding which treatment option is more appropriate and
thus the variations in rates may be clinically appropriate.
For instance, in other conditions, such as renal transplan-
tation, there is evidence of underuse of transplantation




 which is not
explained by black patients’ desire for renal transplanta-




Hoffman et al. also report significant sociodemographic
differences between their African-American and non-Hispanic
white patients. African Americans were less educated (18%
vs 45% were college graduates), had higher levels of co-
morbidity (20% vs 11%), and reported that their treatment
decisions were influenced to a greater extent by insurance
factors (18% vs 11%). These factors must be considered in
evaluating any plan to reduce racial disparities.
What can be done to reduce these disparities? For con-
ditions in which there is uncertainty, as in prostate cancer
screening and treatment, “decision aids”—such as those
used in Frosch’s study—may help patients understand the
probable benefits and risks of different decisions; consider
how they value those benefits and risks; and participate





 Cancer-related decision aids have already been
shown to reduce decisional conflict; assist those who are
uncertain at baseline to make a choice; and increase the





 While decision aids have not yet been
shown to reduce “inappropriate” practice variation, they
may help reduce this variation by having choices reflect
patient preferences.
Decision aids, however, cannot replace the discussions
that are needed between patients and their health care pro-
viders. This is particularly true for African Americans and
those patients with less education, as they already are at
risk of making less informed decisions. With these patients,
physicians use a less-participatory decision-making style,





 Thus, as new decision aids are developed, we must
evaluate their cost, ease of administration, effectiveness in
transmitting information, and accessibility to a population
that includes minorities and less educated patients. Simi-








becoming physicians, we must assure that the students are
trained in how to listen to their patients and assist their
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